Grufity logoGrufity logo

TXMD

4.45USD+0.08(+1.83%)Market Closed

TherapeuticsMD Inc

Market Summary

USD4.45+0.08Market Closed
1.83%

TXMD Alerts

TXMD Stock Price

RSI Chart

Valuation

Market Cap

56.2M

Price/Earnings

-2.07

Price/Sales

0.61

Price/Cashflow

-0.46

MarketCap/EBT

-2.11

Price/Sales

Profitability

EBT Margin

-28.89%

Return on Assets

-18.54%

Fundamentals

Revenue

Revenue (TTM)

87.5M

Revenue Y/Y

-17.67%

Revenue Q/Q

-26.76%

Earnings

Earnings (TTM)

-8.6M

Earnings Y/Y

38.92%

Earnings Q/Q

-125.8%

Price Action

52 Week Range

30.50
(Low)(High)

Last 7 days

-0.2%

Last 30 days

-18.5%

Last 90 days

-56.3%

Trailing 12 Months

-82.2%

Financial Health

Current Ratio

0.6

Debt/Cashflow

-1.35

Investor Care

Shares Dilution (1Y)

11.40%

Diluted EPS (TTM)

-1.43

Peers (Alternatives to TherapeuticsMD)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
459.8B
96.0B
5.64% 16.86%
24
4.79
5.02% 7.14%
342.0B
29.2B
5.87% 53.25%
60.08
11.76
5.34% 1.02%
266.2B
99.7B
9.09% -0.90%
9.08
2.63
43.92% 53.21%
255.3B
57.2B
10.70% 54.15%
15.4
4.47
35.88% 197.59%
163.4B
46.7B
4.75% 50.97%
24.47
3.5
2.79% 223.53%
MID-CAP
5.5B
4.4B
-19.59% -9.60%
-46.93
1.26
1.80% 57.67%
SMALL-CAP
1.9B
628.4M
27.93% -51.99%
-4.08
3.1
64.35% -18.14%
1.9B
659.0M
9.23% 20.30%
32.36
2.95
16.78% -53.92%
1.5B
-
32.82% -58.59%
-0.54
1.95
-4.11% -144.36%
1.2B
112.7M
16.50% -21.36%
-10.75
7.76
-54.94% 40.20%
1.1B
3.1M
16.81% -54.64%
-3.57
108.75
-77.09% -12.24%
945.9M
373.2M
0.99% -19.37%
4.56
2.34
-0.39% -38.45%
564.6M
960.1M
-12.82% -37.97%
11.48
0.6
12.58% -4.36%
56.2M
87.5M
-18.50% -82.20%
-2.07
0.61
-3.70% 94.96%
50.2M
-
98.52% -31.86%
-2.54
1.3
4.98% -2206.95%

Financials for TherapeuticsMD

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue-4.9%8792868791
Gross Profit-4.1%6972676871
Operating Expenses-11.5%171193204208210
  S&GA Expenses-11.5%8495103108154
  R&D Expenses-8.2%66678
Earnings Before Taxes68.5%-8.37-26.57-182.05-172.41-171.54
Net Income68.1%-8.64-27.10-182.03-172.41-171.54
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-8.4%134146133169210
  Current Assets-11.3%879984119160
    Cash Equivalents2.1%38383065105
  Inventory9.0%76987
  Net PPE-22.4%11111
Liabilities5.8%182172274263267
  Current Liabilities6.1%17416426525386
  Long Term Debt3.1%9491203188187
    LT Debt, Current3.1%949120318815
    LT Debt, Non Current-100.0%-172---
  Retained Earnings-2.9%-1,017.06-988.10-1,100.38-1,051.36-1,008.40
  Additional Paid-In Capital0.2%962960957951-
Accumulated Depreciation5.6%33332
Shares Outstanding6.9%99998
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Thousands)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations15.7%-103,408.00-122,711.00-133,839.00-142,693.00-133,456.96
  Share Based Compensation-17.7%13,93316,92717,20818,12514,934
Cashflow From Investing0.1%140,802140,651-1,997.00-2,223.00-1,203.00
Cashflow From Financing-13.2%-103,905.00-91,811.0028,603129,552159,902

Risks

What is the probability of a big loss on TXMD?

100%


Probability that TherapeuticsMD stock will be more than 20% underwater in next one year

97.7%


Probability that TherapeuticsMD stock will be more than 30% underwater in next one year.

86.2%


Probability that TherapeuticsMD stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does TXMD drawdown profile look like?

Y-axis is the maximum loss one would have experienced if TherapeuticsMD was unfortunately bought at previous high price.

Returns

Cumulative Returns on TXMD

-28.4%


10-Year Cumulative Returns

-46.2%


7-Year Cumulative Returns

-57.2%


5-Year Cumulative Returns

-66.5%


3-Year Cumulative Returns

What are the long-term rolling returns for TXMD?

FIve years rolling returns for TherapeuticsMD.

Which funds bought or sold TXMD recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-15
HARBOUR INVESTMENTS, INC.
UNCHANGED
-
-
-
-%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
SOLD OFF
-
-
-
-%
2022-11-15
BNP PARIBAS ARBITRAGE, SNC
NEW
-
2,065
2,065
-%
2022-11-15
STATE STREET CORP
SOLD OFF
-100
-303,000
-
-%
2022-11-14
BRIDGEWAY CAPITAL MANAGEMENT, LLC
NEW
-
100,000
100,000
-%
2022-11-14
ROYAL BANK OF CANADA
-
-
5,000
7,000
-%
2022-11-14
VANGUARD GROUP INC
-
-
-1,911,000
1,729,000
-%
2022-11-14
GEODE CAPITAL MANAGEMENT, LLC
-
-
-729,000
-
-%
2022-11-14
MILLENNIUM MANAGEMENT LLC
-
-
19,000
593,000
-%
2022-11-14
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
-
-
-
1,000
-%

1–10 of 42

Latest Funds Activity

Are funds buying TXMD calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own TXMD

TherapeuticsMD News

InvestorsObserver

Should You Accumulate TherapeuticsMD Inc (TXMD) Stock Friday?.9 days ago

TXMD Fair Value

Recent SEC filings of TherapeuticsMD

View All Filings
Date Filed Form Type Document
Nov 14, 2022
10-Q
Quarterly Report
Nov 14, 2022
8-K
Current Report
Nov 14, 2022
D
D
Oct 31, 2022
4
Insider Trading
Oct 31, 2022
8-K
Current Report
Oct 17, 2022
D
D
Oct 03, 2022
4
Insider Trading
Oct 03, 2022
4
Insider Trading
Oct 03, 2022
4
Insider Trading
Oct 03, 2022
4
Insider Trading

Latest Insider Trading transactions for TXMD

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-10-28
Rubric Capital Management LP
BOUGHT
7,000,000
1,000
7,000
-
2022-09-30
Rubric Capital Management LP
BOUGHT
7,000,000
1,000
7,000
-
2022-08-18
Collins Cooper C.
ACQUIRED
-
-
1,984
-
2022-08-18
Naughton Gail K
ACQUIRED
-
-
1,984
-
2022-08-18
BISARO PAUL
ACQUIRED
-
-
1,984
-
2022-08-18
MUSING JULES A.
ACQUIRED
-
-
1,984
-
2022-08-18
Ling Karen
ACQUIRED
-
-
1,984
-
2022-08-18
Russell Angus C.
ACQUIRED
-
-
1,984
-
2022-08-18
Thompson Tommy G
ACQUIRED
-
-
2,976
-
2022-07-29
Rubric Capital Management LP
BOUGHT
12,333,200
822.21
15,000
-

1–10 of 50

Hugh O'Dowd
420
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

TXMD Income Statement

2022-09-30
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Total revenue, net$ 20,917,000$ 25,406,000$ 68,811,000$ 68,273,000
Cost of goods sold3,788,0005,282,00013,388,00014,101,000
Total gross profit17,129,00020,124,00055,423,00054,172,000
Operating expenses:    
Selling and marketing19,129,00030,005,00061,703,00086,193,000
General and administrative17,635,00028,435,00055,445,00066,691,000
Research and development1,112,0001,605,0004,092,0005,666,000
Total operating expenses37,876,00060,045,000121,240,000158,550,000
Loss from operations(20,747,000)(39,921,000)(65,817,000)(104,378,000)
Other (expense) income:    
Gain on sale of business  143,384,000 
Expense for accretion of Mandatory Redeemable Preferred Stock(3,457,000) (3,457,000) 
Fair value loss on Lender Warrants derivative liability(76,000) (76,000) 
Loss on extinguishment of debt  (8,380,000) 
Interest expense and other financing costs(4,833,000)(7,518,000)(30,941,000)(25,341,000)
Other (expense) income, net(112,000)19,000(128,000)264,000
Total other (expense) income, net(8,478,000)(7,499,000)100,402,000(25,077,000)
(Loss) income before income taxes(29,225,000)(47,420,000)34,585,000(129,455,000)
(Benefit) provision for income taxes(260,000)0290,0000
Net (loss) income$ (28,965,000)$ (47,420,000)$ 34,295,000$ (129,455,000)
(Loss) earnings per common share, basic$ (3.13)$ (5.62)$ 3.86$ (16.68)
Weighted average common shares, basic9,2618,4448,8777,762
(Loss) earnings per common share, diluted$ (3.13)$ (5.62)$ 3.73$ (16.68)
Weighted average common shares, diluted9,2618,4449,2057,762
Comprehensive (loss) income:    
Net (loss) income$ (28,965,000)$ (47,420,000)$ 34,295,000$ (129,455,000)
Comprehensive (loss) income(28,965,000)(47,420,000)34,295,000(129,455,000)
Product [Member]    
Total revenue, net$ 20,917,00024,456,00068,327,00067,039,000
License and Service [Member]    
Total revenue, net $ 950,000$ 484,000$ 1,234,000

TXMD Balance Sheet

2022-09-30
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash$ 27,080$ 65,122
Restricted cash11,250 
Accounts receivable, net of allowance for credit losses of $1,621 and $1,334 as of September 30, 2022 and December 31, 2021, respectively32,15736,176
Inventory6,7017,622
Prepaid and other current assets10,29010,548
Total current assets87,478119,468
Fixed assets, net5511,199
License rights and other intangible assets, net37,87640,318
Right of use assets7,7498,234
Other non-current assets253253
Total assets133,907169,472
Current liabilities:  
Debt, net93,602188,269
Lender Warrants derivative liability2,058 
Make-whole payment derivative liability1,751 
Mandatory Redeemable Preferred Stock19,709 
Accounts payable13,38320,318
Accrued expenses and other current liabilities43,56844,304
Total current liabilities174,071252,891
Operating lease liabilities7,5538,063
Other non-current liabilities5542,139
Total liabilities182,178263,093
Commitments and contingencies (Note 9)
Stockholders' deficit:  
Preferred stock, par value $0.001; 10,000 shares authorized, 22 issued and included in liabilities due to their redemption provisions
Common stock, par value $0.001; 12,000 shares authorized, 9,467 and 8,598 (adjusted for the 50-for-1 reverse stock split) shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively99
Additional paid-in capital968,785957,730
Accumulated deficit(1,017,065)(1,051,360)
Total stockholders' deficit(48,271)(93,621)
Total liabilities and stockholders' deficit$ 133,907$ 169,472